PASG News and Press, Passage Bio Inc.

2026-06-25 02:12:11 ET Passage Bio, Inc. (PASG) M&A Call June 24, 2026 4:30 PM EDT Company Participants Kathleen Borthwick - Senior VP, CFO, Principal Financial Officer & Principal Accounting Officer William Chou - President, CEO & Director Peter Smith ...

2026-06-24 16:15:22 ET More on Passage Bio Seeking Alpha’s Quant Rating on Passage Bio Historical earnings data for Passage Bio Financial information for Passage Bio Read the full article on Seeking Alpha For further details see: Passage Bi...

Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin Remix’s lead program, REM-422, is an orally available mRNA degrader targeting MYB, a ...

2026-06-10 08:15:08 ET UBS analyst issues NEUTRAL recommendation for PASG on June 10, 2026 10:58AM ET. PASG was trading at $5.57 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy, 5 - Hold recommend...

2026-04-21 08:15:10 ET from Wedbush issued a price target of $8.00 for PASG on 2026-04-21 10:52:28. The adjusted price target was set to $8.00. At the time of the announcement, PASG was trading at $6.25. The overall price target consensus is at $7.00 with high price of $...

PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels  FDA feedback from recent Type C meeting indicated a randomized controlled registrational trial will be required ...

2026-03-03 15:03:06 ET More on Passage Bio Seeking Alpha’s Quant Rating on Passage Bio Historical earnings data for Passage Bio Financial information for Passage Bio Read the full article on Seeking Alpha For further details see: Passage Bi...

Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study On track to report updated interim safety and biomarker data from upliFT-D and obtain regulatory feedback on FTD-GRN registrationa...

GitLab Inc. (GTLB) is expected to report $-0.02 for Q4 2026 Ross Stores Inc. (ROST) is expected to report $1.88 for Q4 2026 Advantage Solutions Inc. (ADV) is expected to report $0.07 for Q4 2025 Hyster-Yale Inc. Class A (HY) is expected to report $-1.2 for Q4 2025 Versant Media Gr...

2026-03-02 17:33:38 ET Passage Bio, Inc. (PASG) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in PASG stock price following earnings has averaged ±2.82% , with a median of 2.37%. Th...